Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016)
NCT00432237
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
1703
Enrollment
INDUSTRY
Sponsor class
Conditions
Migraine
Interventions
DRUG:
MK0974 50 mg
DRUG:
MK0974 150 mg
DRUG:
MK0974 300 mg
DRUG:
Comparator: Placebo
Sponsor
Merck Sharp & Dohme LLC